Denali Therapeutics (NASDAQ:DNLI) Upgraded to Buy at Stifel Nicolaus

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) was upgraded by equities research analysts at Stifel Nicolaus from a "hold" rating to a "buy" rating in a note issued to investors on Monday, Marketbeat reports. The firm presently has a $37.00 price objective on the stock. Stifel Nicolaus' price objective points to a potential upside of 58.87% from the stock's current price.

A number of other equities analysts have also issued reports on DNLI. HC Wainwright restated a "buy" rating and set a $90.00 target price on shares of Denali Therapeutics in a research report on Thursday, November 7th. Raymond James restated a "market perform" rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. Jefferies Financial Group raised their target price on shares of Denali Therapeutics from $40.00 to $45.00 and gave the stock a "buy" rating in a research report on Friday, November 1st. JPMorgan Chase & Co. lowered their target price on shares of Denali Therapeutics from $29.00 to $28.00 and set an "overweight" rating on the stock in a research report on Friday, October 11th. Finally, Bank of America raised their target price on shares of Denali Therapeutics from $25.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, September 4th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $40.40.

Denali Therapeutics Stock Up 1.4 %

Denali Therapeutics stock traded up $0.32 during mid-day trading on Monday, hitting $23.29. The company had a trading volume of 1,000,377 shares, compared to its average volume of 1,050,320. The stock has a market cap of $3.35 billion, a price-to-earnings ratio of -8.49 and a beta of 1.35. Denali Therapeutics has a 1 year low of $14.56 and a 1 year high of $33.33. The business has a fifty day moving average of $26.28 and a 200 day moving average of $24.85.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter in the prior year, the firm posted ($0.72) EPS. Equities analysts anticipate that Denali Therapeutics will post -2.71 earnings per share for the current year.

Insider Activity at Denali Therapeutics

In other Denali Therapeutics news, insider Alexander O. Schuth sold 15,558 shares of the firm's stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $29.91, for a total value of $465,339.78. Following the completion of the sale, the insider now owns 178,066 shares of the company's stock, valued at approximately $5,325,954.06. This trade represents a 8.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Steve E. Krognes sold 30,000 shares of the firm's stock in a transaction on Monday, September 30th. The shares were sold at an average price of $29.03, for a total value of $870,900.00. Following the completion of the sale, the director now directly owns 29,096 shares of the company's stock, valued at approximately $844,656.88. This trade represents a 50.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 86,578 shares of company stock worth $2,474,440 in the last three months. Insiders own 7.90% of the company's stock.

Institutional Investors Weigh In On Denali Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of DNLI. FMR LLC raised its stake in shares of Denali Therapeutics by 3,234.3% during the 3rd quarter. FMR LLC now owns 7,831,378 shares of the company's stock worth $228,128,000 after buying an additional 7,596,508 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Denali Therapeutics by 63.2% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company's stock worth $109,223,000 after buying an additional 1,451,770 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Denali Therapeutics during the 2nd quarter worth $24,454,000. Wellington Management Group LLP raised its stake in shares of Denali Therapeutics by 9.2% during the 3rd quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company's stock worth $312,491,000 after buying an additional 903,683 shares during the last quarter. Finally, Integral Health Asset Management LLC acquired a new position in shares of Denali Therapeutics during the 2nd quarter worth $7,546,000. Institutional investors and hedge funds own 92.92% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.